Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation

American Journal of Respiratory Cell and Molecular Biology

Volumn 46, Issue 3, 2012, Pages 372-379

  Li, Yingji ^a   Connolly, Michelle ^c   Nagaraj, Chandran ^a   Tang, Bi ^a   Bálint, Zoltan ^a,e   Popper, Helmut ^a   Smolle Juettner, Freyja M ^b   Lindenmann, Jörg ^b   Kwapiszewska, Grazyna ^d   Aaronson, Philipp I ^c   Wohlkoenig, Christoph ^a   Leithner, Katharina ^a   Olschewski, Horst ^a,e   Olschewski, Andrea ^a,e  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Potassium channels; PPAR; Prostacyclin; Pulmonary circulation; Vascular smooth muscle

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CYCLIC AMP DEPENDENT PROTEIN KINASE; ILOPROST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; POTASSIUM CHANNEL; PROSTACYCLIN; PROSTANOID RECEPTOR; UNIPROST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PULMONARY ARTERY; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASODILATATION;

ANIMALS; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; GENE SILENCING; HUMANS; ILOPROST; MALE; MEMBRANE POTENTIALS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PPAR DELTA; PPAR GAMMA; PULMONARY ARTERY; RATS; RATS, WISTAR; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; VASODILATION; VASODILATOR AGENTS;

EID: 84863298193     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0428OC     Document Type: Article

References (26)

1. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329. (Pubitemid 34815354)
2. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:891-901.
3. Nikam VS, Schermuly RT, Dumitrascu R, Weissmann N, Kwapiszewska G, Morrell N, Klepetko W, Fink L, Seeger W, Voswinckel R. Treprostinil inhibits the recruitment of bone marrow derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J 2010;36:1302-1314.
4. Norel X, Walch L, Gascard JP, deMontpreville V, Brink C. Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone. Br J Pharmacol 2004;142:788-796. (Pubitemid 38969674)
5. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268:C799-C822.
6. Gurney AM, Osipenko ON, MacMillan D, Kempsill FE. Potassium channels underlying the resting potential of pulmonary artery smooth muscle cells. Clin Exp Pharmacol Physiol 2002;29:330-333. (Pubitemid 34227069)
7. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, Wilhelm J, Morty RE, Brau ME, Weir EK, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006;98:1072-1080.
8. Lim H, Dey SK. A novel pathway of prostacyclin signaling: hanging out with nuclear receptors. Endocrinology 2002;143:3207-3210. (Pubitemid 34925693)
9. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688. (Pubitemid 30650602)
10. Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 2009;18:128-133.
11. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009;29:706-711.
12. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, Mitchell JA. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 2006;34:242-246. (Pubitemid 43202472)
13. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J 2006;20:326-328. (Pubitemid 46671159)
14. Harrington LS, Moreno L, Reed A, Wort SJ, Desvergne B, Garland C, Zhao L, Mitchell JA. The PPARbeta/delta agonist GW0742 relaxespulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS ONE 2010;5:e9526.
15. i to hypoxia in pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002; 283:L1143-L1150.
16. Auer-Grumbach M, Olschewski A, Papic L, Kremer H, McEntagart ME, Uhrig S, Fischer C, Frohlich E, Balint Z, Tang B, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet 2010;42:160-164.
17. Tang B, Li Y, Nagaraj C, Morty RE, Gabor S, Stacher E, Voswinckel R, Weissmann N, Leithner K, Olschewski H, et al. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2009;41:476-483.
18. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-75.
19. Christman BW. Lipid mediator dysregulation in primary pulmonary hypertension. Chest 1998;114:205S-207S. (Pubitemid 28435969)
20. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-1932. (Pubitemid 29275065)
21. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
22. Resnik E, Herron J, Fu R, Ivy DD, Cornfield DN. Oxygen tension modulates the expression of pulmonary vascular BKCa channel alpha- and beta-subunits. Am J Physiol Lung Cell Mol Physiol 2006;290:L761-L768. (Pubitemid 43725082)
23. Peinado VI, Paris R, Ramirez J, Roca J, Rodriguez-Roisin R, Barbera JA. Expression of BK(Ca) channels in human pulmonary arteries: relationship with remodeling and hypoxic pulmonary vasoconstriction. Vascul Pharmacol 2008;49:178-184.
24. Walch L, Labat C, Gascard JP, de Montpreville V, Brink C, Norel X. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol 1999;126:859-866. (Pubitemid 29103701)
25. Bley KR, Bhattacharya A, Daniels DV, Gever J, Jahangir A, O'Yang C, Smith S, Srinivasan D, Ford AP, Jett MF. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol 2006;147:335-345. (Pubitemid 43214691)
26. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, Grillot DA, Iannone MA, Lazar MA, Willson TM, Billin AN. Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol 2008;22:523-529. (Pubitemid 351185947)